A Phase I Study of the WT1 peptide vaccine for the post-transplant AML at 2nd remission

A Phase I Study of the WT1 peptide vaccine for the post-transplant AML at 2nd remission - A Phase I Study of the WT1 peptide vaccine for the post-transplant AM Lat 2nd remission

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013289

Enrollment

Registered

2014-04-01

Start date

2014-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia 2nd remission(post allogeneic stem cell transplantation)

Interventions

Phase1 trial WT1 peptide vaccine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients less than 20 years old. 2.Patients who achieved 2nd remission after 1st relapse 3.Patients who underwent stem cell transplantation(SCT). 4.WT1 mRNA copy number of tumor cells is more than 1000 copies / microgRNA or more than 50 copies / microgRNA 5.The ECOG performance status is a 0-3.

Exclusion criteria

Exclusion criteria: 1.Patients with Down syndrome 2.Patients who relapsed less than 6 months after the end of initial therapy 3.Patients who suffered from uncontrollable infection and organ failure 4.Patients who suffered from active GVHD

Design outcomes

Primary

Measure	Time frame
Primary endpoint is immune monitoring.	—

Secondary

Measure	Time frame
Secondary endpoint is 2 yerar relapse rate.	—

Countries

Japan

Contacts

Public ContactTakako Miyamura,Yoshiko Hashii

Osaka University Graduate school of medicine pediatricis

miyamu@ped.med.osaka-u.ac.jp06-6879-3932

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026